Field notes on the literature
Ipamorelin is detectable in urine at two to ten picograms per millilitre — which is where its story, watched closely, gets interesting.
A naturalist's digest of the molecule the anti-doping labs learned to see: how it is detected, where it stands with regulators, and what three decades of studies actually measured. Every number is cited.
Start here
Ipamorelin is a small synthetic peptide — five amino acids long — that tells the pituitary gland to release a pulse of growth hormone. It belongs to a family called growth hormone secretagogues (compounds that coax the body into making its own growth hormone rather than supplying it directly). Its claim to fame is selectivity: it raises growth hormone cleanly, without stirring up the stress hormone cortisol the way older peptides in its class do [1].
It has never been approved as a medicine, anywhere. The one human trial that reached a meaningful stage tested it for sluggish bowels after surgery and did not work [3]. Most of what people say about it for sleep, recovery, and fat loss comes from research-use communities, not controlled studies — and what people report, including the downsides, is gathered on the effects page.
One thing the labs are sure of: ipamorelin is banned in sport and shows up in urine tests at picogram concentrations [7]. "Meds" in this site's name is a watchword, not a pharmacy — this is editorial commentary on published science, with no product behind it.
The molecule the anti-doping labs learned to see
Most peptides this small slip through routine drug screens. Ipamorelin does not — not anymore. In 2012 a method using nano-scale liquid chromatography coupled to a benchtop Orbitrap mass spectrometer (an instrument that weighs molecular fragments with very high precision) screened eleven prohibited peptides, ipamorelin among them, in human urine down to limits of detection of 2 to 10 pg/mL [7]. That is a vanishingly small amount — picograms, trillionths of a gram per millilitre.
The detection work did not stop there. A high-throughput tandem mass-spectrometry method picked ipamorelin out of equine and human urine alongside seven related growth-hormone-releasing peptides, confirming all eight (or their breakdown products) in rat urine after intravenous dosing [8]. Earlier work had already determined ipamorelin and seven other peptides in human urine at 0.2 to 1 ng/mL and, using a retrospective full-scan approach, turned up previously unknown metabolites [9]. Analysts even mapped the urinary fingerprint left after nasal dosing [10].
The practical upshot is plain: ipamorelin is a prohibited substance in sport with established, validated urine detection. The World Anti-Doping Agency lists growth hormone secretagogues under category S2, banned at all times.
What the studies actually measured
Strip away the marketing and the cited record is small but consistent. In its founding 1998 characterization, ipamorelin released growth hormone potently in rat pituitary cells, in anaesthetised rats, and in conscious swine — with a swine ED50 (the dose producing half the maximal effect) of 2.3 nmol/kg, slightly more potent than the older peptide GHRP-6 at 3.9 nmol/kg — yet did not raise cortisol even at doses more than 200 times its growth-hormone threshold [1].
In humans, a 1999 pharmacokinetic study in eight healthy men per dose found dose-proportional kinetics, a terminal half-life of roughly 2 hours, and a single discrete growth-hormone pulse peaking about 40 minutes after dosing [2]. In rats, subcutaneous ipamorelin dose-dependently raised the longitudinal bone-growth rate over 15 days [4]. The freshest in-vivo work, a 2024 ferret study, found ipamorelin blunted chemotherapy-driven weight loss by about 24% in the delayed phase, though without any anti-nausea effect [5].
The honest summary: large, reproducible effects on growth-hormone release in animals and acute human pharmacology — and a single completed efficacy trial that missed [3]. You can follow the molecule's Ipamorelin research chapter by chapter, or jump to the Ipamorelin references.
Where this fits in the secretagogue field
Ipamorelin rarely travels alone in the wild. In research-use communities it is most often paired with CJC-1295, a growth-hormone-releasing-hormone analog (a different kind of peptide that works through a separate receptor). The two act by complementary mechanisms, which is the pharmacological rationale behind the combination — though no controlled trial has ever tested the pair for any outcome.
That distinction matters for anyone trying to make sense of the category. Ipamorelin is a GHRP — it acts on the ghrelin receptor. Sermorelin and tesamorelin are GHRH analogs — they act on the growth-hormone-releasing-hormone receptor. Same destination (more growth hormone), different doors. The research page works through these comparisons — Ipamorelin effects covers what people report from the combinations, while the science of each pairing is laid out alongside the single-agent data.